vs
Graham Holdings Co（GHC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Graham Holdings Co的季度营收约是Revvity的1.6倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs 8.7%，领先4.0%），Revvity同比增速更快（5.9% vs 0.4%），Revvity自由现金流更多（$161.8M vs $5.0M），过去两年Revvity的营收复合增速更高（9.0% vs 4.2%）
Graham Holdings是一家总部位于美国弗吉尼亚州阿灵顿县、在特拉华州注册的多元化综合控股集团，曾持有知名媒体《华盛顿邮报》与《新闻周刊》的所有权，旗下业务覆盖多个领域，在北美市场拥有深厚的行业运营积淀。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GHC vs RVTY — 直观对比
营收规模更大
GHC
是对方的1.6倍
$772.1M
营收增速更快
RVTY
高出5.4%
0.4%
净利率更高
RVTY
高出4.0%
8.7%
自由现金流更多
RVTY
多$156.8M
$5.0M
两年增速更快
RVTY
近两年复合增速
4.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $108.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 3.8% | 14.5% |
| 净利率 | 8.7% | 12.7% |
| 营收同比 | 0.4% | 5.9% |
| 净利润同比 | -80.2% | 3.9% |
| 每股收益（稀释后） | $24.76 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHCRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润GHCRVTY
| Q4 25 | $108.7M | $98.4M | ||
| Q3 25 | $122.9M | $46.7M | ||
| Q2 25 | $36.7M | $53.9M | ||
| Q1 25 | $23.9M | $42.2M | ||
| Q4 24 | $548.8M | $94.6M | ||
| Q3 24 | $72.5M | $94.4M | ||
| Q2 24 | $-21.0M | $55.4M | ||
| Q1 24 | $124.4M | $26.0M |
毛利率GHCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率GHCRVTY
| Q4 25 | 3.8% | 14.5% | ||
| Q3 25 | 5.2% | 11.7% | ||
| Q2 25 | 6.0% | 12.6% | ||
| Q1 25 | 4.1% | 10.9% | ||
| Q4 24 | 5.8% | 16.3% | ||
| Q3 24 | 6.8% | 14.3% | ||
| Q2 24 | 2.2% | 12.4% | ||
| Q1 24 | 3.1% | 6.8% |
净利率GHCRVTY
| Q4 25 | 8.7% | 12.7% | ||
| Q3 25 | 9.6% | 6.7% | ||
| Q2 25 | 3.0% | 7.5% | ||
| Q1 25 | 2.0% | 6.4% | ||
| Q4 24 | 44.1% | 13.0% | ||
| Q3 24 | 6.0% | 13.8% | ||
| Q2 24 | -1.8% | 8.0% | ||
| Q1 24 | 10.8% | 4.0% |
每股收益（稀释后）GHCRVTY
| Q4 25 | $24.76 | $0.86 | ||
| Q3 25 | $27.91 | $0.40 | ||
| Q2 25 | $8.35 | $0.46 | ||
| Q1 25 | $5.45 | $0.35 | ||
| Q4 24 | $124.05 | $0.77 | ||
| Q3 24 | $16.42 | $0.77 | ||
| Q2 24 | $-4.79 | $0.45 | ||
| Q1 24 | $27.72 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $267.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.8B | $7.3B |
| 总资产 | $8.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHCRVTY
| Q4 25 | $267.0M | $919.9M | ||
| Q3 25 | $190.8M | $931.4M | ||
| Q2 25 | $176.2M | $991.8M | ||
| Q1 25 | $156.7M | $1.1B | ||
| Q4 24 | $260.9M | $1.2B | ||
| Q3 24 | $244.4M | $1.2B | ||
| Q2 24 | $140.7M | $2.0B | ||
| Q1 24 | $130.9M | $1.7B |
股东权益GHCRVTY
| Q4 25 | $4.8B | $7.3B | ||
| Q3 25 | $4.5B | $7.4B | ||
| Q2 25 | $4.4B | $7.6B | ||
| Q1 25 | $4.3B | $7.6B | ||
| Q4 24 | $4.3B | $7.7B | ||
| Q3 24 | $4.0B | $7.9B | ||
| Q2 24 | $4.0B | $7.9B | ||
| Q1 24 | $4.0B | $7.8B |
总资产GHCRVTY
| Q4 25 | $8.4B | $12.2B | ||
| Q3 25 | $7.9B | $12.1B | ||
| Q2 25 | $7.6B | $12.4B | ||
| Q1 25 | $7.6B | $12.4B | ||
| Q4 24 | $7.7B | $12.4B | ||
| Q3 24 | $7.4B | $12.8B | ||
| Q2 24 | $7.2B | $13.4B | ||
| Q1 24 | $7.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $5.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 0.4% | 21.0% |
| 资本支出强度资本支出/营收 | 1.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.26× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $275.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GHCRVTY
| Q4 25 | $28.3M | $182.0M | ||
| Q3 25 | $178.1M | $138.5M | ||
| Q2 25 | $94.8M | $134.3M | ||
| Q1 25 | $46.0M | $128.2M | ||
| Q4 24 | $116.3M | $174.2M | ||
| Q3 24 | $237.6M | $147.9M | ||
| Q2 24 | $52.0M | $158.6M | ||
| Q1 24 | $1.1M | $147.6M |
自由现金流GHCRVTY
| Q4 25 | $5.0M | $161.8M | ||
| Q3 25 | $161.8M | $120.0M | ||
| Q2 25 | $78.0M | $115.5M | ||
| Q1 25 | $30.5M | $112.2M | ||
| Q4 24 | $91.1M | $149.8M | ||
| Q3 24 | $219.4M | $125.6M | ||
| Q2 24 | $33.7M | $136.6M | ||
| Q1 24 | $-20.2M | $129.7M |
自由现金流率GHCRVTY
| Q4 25 | 0.4% | 21.0% | ||
| Q3 25 | 12.6% | 17.2% | ||
| Q2 25 | 6.4% | 16.0% | ||
| Q1 25 | 2.6% | 16.9% | ||
| Q4 24 | 7.3% | 20.5% | ||
| Q3 24 | 18.2% | 18.4% | ||
| Q2 24 | 2.8% | 19.7% | ||
| Q1 24 | -1.8% | 20.0% |
资本支出强度GHCRVTY
| Q4 25 | 1.9% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 1.5% | 3.2% | ||
| Q1 24 | 1.8% | 2.7% |
现金转化率GHCRVTY
| Q4 25 | 0.26× | 1.85× | ||
| Q3 25 | 1.45× | 2.97× | ||
| Q2 25 | 2.58× | 2.49× | ||
| Q1 25 | 1.93× | 3.03× | ||
| Q4 24 | 0.21× | 1.84× | ||
| Q3 24 | 3.28× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 0.01× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GHC
| Products | $602.7M | 48% |
| Kaplan International | $251.9M | 20% |
| Manufacturing | $117.8M | 9% |
| Television Broadcasting | $110.5M | 9% |
| Higher Education | $83.8M | 7% |
| Supplemental Education | $74.9M | 6% |
| Related Party | $4.4M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
